


EBITDA ^(a)



quarterly, fiscal 2013 to present



Fiscal Year	1Q	2Q	3Q	4Q	Year
2017 ^(b)	\$1,751	\$1,692	\$1,502	\$1,812	\$6,757
2016	\$1,858	\$1,818	\$1,631	\$1,960	\$7,267
2015 ^(c)	\$1,694	\$1,881	\$1,437	\$2,731	\$7,743
2014	\$1,533	\$1,560	\$1,439	\$2,130	\$6,664
2013 ^(d)	\$2,104	\$1,794	\$1,444	\$1,823	\$7,166

^(a) Amounts relate to our continuing operations.

^(b) The fourth quarter and full year 2017 consisted of 14 weeks and 53 weeks, respectively, compared with 13 weeks and 52 weeks in the comparable prior-year periods.

^(c) Fourth quarter and full year amounts include a \$620 million gain on sale of our former pharmacy and clinic businesses.

^(d) First quarter and full year amounts include a \$391 million gain on sale of our U.S. credit card receivables portfolio.